Table 2.

Comparison of patient baseline characteristics of analysis set for primary objective on study Day 1

			Tocilizumab (JA42434)	SOC (COVIREGI-JP)	S.D.
			(N = 31.00)	(N = 31.00)
Smoking history		Current	6.00 (19.4%)	1.83 (5.9%)	0.4
		Former	12.00 (38.7%)	15.42 (49.7%)	–0.2
		Never	13.00 (41.9%)	9.25 (29.8%)	0.3
		Unknown	0.00 (0.0%)	4.50 (14.5%)	–0.6
Ordinal scale for clinical status		1	0.00 (0.0%)	0.00 (0.0%)	0.0
		2	3.00 (9.7%)	3.00 (9.7%)	0.0
		3	22.00 (71.0%)	22.00 (71.0%)	0.0
		4	2.00 (6.5%)	2.00 (6.5%)	0.0
		5	4.00 (12.9%)	4.00 (12.9%)	0.0
		6	0.00 (0.0%)	0.00 (0.0%)	0.0
		7	0.00 (0.0%)	0.00 (0.0%)	0.0
Mechanical ventilation		Yes	4.00 (12.9%)	4.00 (12.9%)	0.0
		No	27.00 (87.1%)	27.00 (87.1%)	0.0
Concomitant therapy on study Day 1	Steroid use	Yes	19.00 (61.3%)	22.67 (73.1%)	–0.3
		No	12.00 (38.7%)	8.33 (26.9%)	0.3
	Favipiravir use	Yes	9.00 (29.0%)	11.83 (38.2%)	–0.2
		No	22.00 (71.0%)	19.17 (61.8%)	0.2
	Remdesivir use	Yes	10.00 (32.3%)	10.00 (32.3%)	0.0
		No	21.00 (67.7%)	21.00 (67.7%)	0.0
	Plasmapheresis/plasma exchange	Yes	2.00 (6.5%)	0.00 (0.0%)	0.4
		No	29.00 (93.5%)	9.25 (29.8%)	1.7
Concomitant therapy on or after hospitalization Day 1 up to study Day 1	Steroid use	Yes	22.00 (71.0%)	23.67 (76.3%)	–0.1
		No	9.00 (29.0%)	7.33 (23.7%)	0.1
	Favipiravir use	Yes	9.00 (29.0%)	13.33 (43.0%)	–0.3
		No	22.00 (71.0%)	17.67 (57.0%)	0.3
	Remdesivir use	Yes	15.00 (48.4%)	12.00 (38.7%)	0.2
		No	16.00 (51.6%)	19.00 (61.3%)	-0.2
	Plasmapheresis/plasma exchange	Yes	2.00 (6.5%)	0.00 (0.0%)	0.4
		No	29.00 (93.5%)	31.00 (100.0%)	–0.4
Days from COVID-19 diagnosis		Mean (SD)	3.8 (2.0)	4.6 (2.7)	–0.4
Days from COVID-19 first hospitalization		Mean (SD)	4.5 (2.5)	4.5 (2.5)	0.0

SOC Standard treatment for patients with severe COVID-19, S.D. Standardized difference, SD Standard deviation

Weighted analysis was performed as appropriate to the matching ratio, and for weighted analyses, numbers of subjects are expressed to two decimal places